News
Events
Blog
Contact
Ask the Experts
Board of Directors
Volunteers
Careers
What We Do
Integrated Programs
Turnkey solutions for shortening development times
Candidate Development
Selecting the right molecules for development
Early Development
Accelerating molecules through to proof-of-concept
Late Development
Accelerating products through to commercial manufacture
Tailored Services
Individual services to meet customer needs
Drug Substance
Route Scouting, PR&D, Small-Scale GMP Manufacture, DOE/QbD, Isotopic Labeling
Formulation Development
Dosage Forms, Pre-Formulation, Solubilization, Modified Release, Pediatrics
Clinical Trial Manufacturing
Phase I-III Clinical Supplies, Adaptive Manufacturing, High-Potency APIs
Commercial Manufacturing
Tech Transfer, Scale-Up, Registration, Process Validation
Clinical Pharmacology
First-in-Human, BA/BE, Human ADME, Pharmacy Compounding, Isotopic Labeling
Bioanalysis
Biotransformation, Quantitative Biological & Chemical Analysis, Insulin Analogues
Data Sciences
Data Management, Programming, Statistics/PK, Medical Writing
Drug Development Consulting
Scientific Advice, Developability Assessment, Program Design
About Quotient Sciences
At a Glance
We accelerate drug development. Saving precious time in getting medicines to patients.
Translational Pharmaceutics®
Our flagship platform for accelerating drug development.
Our Manifesto
We believe molecules need to become cures, fast. Because humanity needs solutions, fast.
Life at Quotient
Explore how team work is the key to our success
Science, Agility, Culture
Finding creative solutions, delivering for our customers.
Awards & Achievements
We have been recognized with various awards throughout the years. Take a look now.
Resources
Whitepaper
Accelerating the Development of Oncology Medicines
Oncology drugs dominate today’s research focus with over >5500 molecules in development, representing over 35% …
Whitepaper
Accelerating the Developing of Orphan Drugs for Rare Diseases
Worldwide there are over 300 million people living with identified rare diseases. This white paper …
Case Studies
Druggability Technologies
Druggability Technologies (DRGT) is developing DRGT-46 as a novel therapy for pain. Gabor Heltovics, former …
Resources
Case studies
Info sheets
Scientific posters
Whitepapers
Webinars
What We Do
Back
What We Do
Integrated Programs
Back
What We Do
Candidate Development
Early Development
Late Development
Tailored Services
Back
What We Do
Drug Substance
Formulation Development
Clinical Trial Manufacturing
Commercial Manufacturing
Clinical Pharmacology
Bioanalysis
Data Sciences
Drug Development Consulting
About Quotient Sciences
Back
About Quotient Sciences
At a Glance
Translational Pharmaceutics®
Our Manifesto
Life at Quotient
Science, Agility, Culture
Awards & Achievements
Resources
Back
Resources
Case studies
Info sheets
Scientific posters
Whitepapers
Webinars
Careers
Quick links
Back
News
Events
Blog
Contact
Ask the Experts
Board of Directors
Volunteers
Press enter to search
Suggested searches
Early Development
Candidate Selection
Late Development
ADME
Translational Pharmaceutics
Blog
Topic
505(b)(2)
ADME
Bioanalysis
Biopharmaceutics
Candidate Development
Clinical Pharmacology
Clinical Trial Manufacturing
Data Integrity
Drug Development Consultancy
Drug Substance
Drug Substance to Drug Product
Early Development
Formulation Development
HPAPIs
Industry Collaboration
Inhalation
Innovation Within Drug Development
Microbiology
Modeling and Simulation
Modified-Release Drug Products
Oncology
Orphan Drug Development
Pediatric Drug Development
Peptides
Pharmacy
Project Management
Quality Assurance
Rebranding
Scientific Achievements
Scintigraphy
Site Spotlight
Translational Pharmaceutics
Author
Dr. Peter Scholes
Celina Alvarez
Prasad Challapalli
Nutan Gangrade
Dr. Joseph DiMasi
Harpreet Smith
Nazim Kanji
Antonio Regueira
Dr. Andy Lewis
Clare Preskey
Kimberly Paris
Iain Shaw
Martin Wing-King
Orlaith Greenan
Nick McEntee
Mark Egerton
Ann Church
Greg Johnson
Sarah Stevens
Dr. Paul Quigley
Stuart McDougall
Dr. Gareth Jenkins
Dr. Aruna Railkar
Dr. Vanessa Zann
Dr. Alison Wilby
Gareth Whitaker
Beth Brickhill
Chris Roe
Erika Reategui
Michael Blackburn
John McDermott
Richard Castledine
Stephen Byard
Dr. Asma Patel
Emilie Bergström
Eleanor Row
Russell Scammell
Ian Nisbet
Robert Alfred
Catherine Wilkes
Marian de Armas
Reset filters
Filter
5
/ 5 articles
Formulation Development
Overcoming Challenges with Poorly Soluble Molecules in Early Development
By Emilie Bergström
Formulation Development
Integrated Development Strategies, Part 2: Reformulating for clinical and commercial success
By Dr. Andy Lewis
Formulation Development
How to balance time, costs and development risk when choosing the appropriate dosage form for your first-in-human Phase I trials?
By Dr. Peter Scholes
Formulation Development
Candidate selection & API characterization: How do we assess the right molecules to take forward into development?
Formulation Development
How to Avoid Losing Time in Development when Bridging from First-in-Human Dosage Form to Robust and Scalable Phase II Drug Products
Share Your Development Challenge with our Scientists
Let's Talk
